214 related articles for article (PubMed ID: 28100626)
1. Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction.
Eppinga RN; Kofink D; Dullaart RP; Dalmeijer GW; Lipsic E; van Veldhuisen DJ; van der Horst IC; Asselbergs FW; van der Harst P
Circ Cardiovasc Genet; 2017 Feb; 10(1):. PubMed ID: 28100626
[TBL] [Abstract][Full Text] [Related]
2. Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.
Eppinga RN; Hartman MH; van Veldhuisen DJ; Lexis CP; Connelly MA; Lipsic E; van der Horst IC; van der Harst P; Dullaart RP
PLoS One; 2016; 11(1):e0145719. PubMed ID: 26808474
[TBL] [Abstract][Full Text] [Related]
3. Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction.
de Koning MLY; Westenbrink BD; Assa S; Garcia E; Connelly MA; van Veldhuisen DJ; Dullaart RPF; Lipsic E; van der Harst P
J Am Coll Cardiol; 2021 Oct; 78(14):1421-1432. PubMed ID: 34593124
[TBL] [Abstract][Full Text] [Related]
4. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial.
Lexis CP; van der Horst IC; Lipsic E; Wieringa WG; de Boer RA; van den Heuvel AF; van der Werf HW; Schurer RA; Pundziute G; Tan ES; Nieuwland W; Willemsen HM; Dorhout B; Molmans BH; van der Horst-Schrivers AN; Wolffenbuttel BH; ter Horst GJ; van Rossum AC; Tijssen JG; Hillege HL; de Smet BJ; van der Harst P; van Veldhuisen DJ;
JAMA; 2014 Apr; 311(15):1526-35. PubMed ID: 24687169
[TBL] [Abstract][Full Text] [Related]
5. Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial.
Lexis CP; van der Horst IC; Lipsic E; van der Harst P; van der Horst-Schrivers AN; Wolffenbuttel BH; de Boer RA; van Rossum AC; van Veldhuisen DJ; de Smet BJ;
Cardiovasc Drugs Ther; 2012 Oct; 26(5):417-26. PubMed ID: 22968678
[TBL] [Abstract][Full Text] [Related]
6. Leukocyte telomere length and left ventricular function after acute ST-elevation myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial.
Haver VG; Hartman MH; Mateo Leach I; Lipsic E; Lexis CP; van Veldhuisen DJ; van Gilst WH; van der Horst IC; van der Harst P
Clin Res Cardiol; 2015 Oct; 104(10):812-21. PubMed ID: 25840550
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction.
Al Ali L; Hartman MT; Lexis CP; Hummel YM; Lipsic E; van Melle JP; van Veldhuisen DJ; Voors AA; van der Horst IC; van der Harst P
PLoS One; 2016; 11(12):e0168340. PubMed ID: 27977774
[TBL] [Abstract][Full Text] [Related]
8. Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.
Chen WR; Chen YD; Tian F; Yang N; Cheng LQ; Hu SY; Wang J; Yang JJ; Wang SF; Gu XF
Circ Cardiovasc Imaging; 2016 Dec; 9(12):. PubMed ID: 27940956
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction.
Abualsuod A; Rutland JJ; Watts TE; Pandat S; Delongchamp R; Mehta JL
Cardiovasc Drugs Ther; 2015 Jun; 29(3):265-75. PubMed ID: 26068409
[TBL] [Abstract][Full Text] [Related]
10. ST-elevation myocardial infarction with reduced left ventricular ejection fraction: Insights into persisting left ventricular dysfunction. A pPCI-registry analysis.
Stolfo D; Cinquetti M; Merlo M; Santangelo S; Barbati G; Alonge M; Vitrella G; Rakar S; Salvi A; Perkan A; Sinagra G
Int J Cardiol; 2016 Jul; 215():340-5. PubMed ID: 27128558
[TBL] [Abstract][Full Text] [Related]
11. Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT.
Hartman MHT; Prins JKB; Schurer RAJ; Lipsic E; Lexis CPH; van der Horst-Schrivers ANA; van Veldhuisen DJ; van der Horst ICC; van der Harst P
Clin Res Cardiol; 2017 Dec; 106(12):939-946. PubMed ID: 28755285
[TBL] [Abstract][Full Text] [Related]
12. Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial.
Fonseca FAH; Izar MC; Maugeri IML; Berwanger O; Damiani LP; Pinto IM; Szarf G; França CN; Bianco HT; Moreira FT; Caixeta A; Alves CMR; Soriano Lopes A; Klassen A; Tavares MFM; Fonseca HA; Carvalho ACC;
Trials; 2017 Dec; 18(1):601. PubMed ID: 29258572
[TBL] [Abstract][Full Text] [Related]
13. Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction.
Groot HE; Al Ali L; van der Horst ICC; Schurer RAJ; van der Werf HW; Lipsic E; van Veldhuisen DJ; Karper JC; van der Harst P
Clin Res Cardiol; 2019 Jun; 108(6):612-621. PubMed ID: 30367209
[TBL] [Abstract][Full Text] [Related]
14. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.
Ibanez B; Macaya C; Sánchez-Brunete V; Pizarro G; Fernández-Friera L; Mateos A; Fernández-Ortiz A; García-Ruiz JM; García-Álvarez A; Iñiguez A; Jiménez-Borreguero J; López-Romero P; Fernández-Jiménez R; Goicolea J; Ruiz-Mateos B; Bastante T; Arias M; Iglesias-Vázquez JA; Rodriguez MD; Escalera N; Acebal C; Cabrera JA; Valenciano J; Pérez de Prado A; Fernández-Campos MJ; Casado I; García-Rubira JC; García-Prieto J; Sanz-Rosa D; Cuellas C; Hernández-Antolín R; Albarrán A; Fernández-Vázquez F; de la Torre-Hernández JM; Pocock S; Sanz G; Fuster V
Circulation; 2013 Oct; 128(14):1495-503. PubMed ID: 24002794
[TBL] [Abstract][Full Text] [Related]
15. Intra-coronary morphine versus placebo in the treatment of acute ST-segment elevation myocardial infarction: the MIAMI randomized controlled trial.
Le Corvoisier P; Gallet R; Lesault PF; Audureau E; Paul M; Ternacle J; Ghostine S; Champagne S; Arrouasse R; Bitari D; Mouillet G; Dubois-Randé JL; Berdeaux A; Ghaleh B; Deux JF; Teiger E
BMC Cardiovasc Disord; 2018 Oct; 18(1):193. PubMed ID: 30340532
[TBL] [Abstract][Full Text] [Related]
16. Metformin and Myocardial Injury in Patients With Diabetes and ST-Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis.
Basnet S; Kozikowski A; Makaryus AN; Pekmezaris R; Zeltser R; Akerman M; Lesser M; Wolf-Klein G
J Am Heart Assoc; 2015 Oct; 4(10):e002314. PubMed ID: 26494519
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcomes in patients with cardiogenic shock according to left ventricular function: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme.
Aissaoui N; Riant E; Lefèvre G; Delmas C; Bonello L; Henry P; Bonnefoy E; Schiele F; Ferrières J; Simon T; Danchin N; Puymirat E;
Arch Cardiovasc Dis; 2018 Nov; 111(11):678-685. PubMed ID: 29290598
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
Woo JS; Kim W; Ha SJ; Kim JB; Kim SJ; Kim WS; Seon HJ; Kim KS
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2252-60. PubMed ID: 23868944
[TBL] [Abstract][Full Text] [Related]
19. Augmented glycaemic gap is a marker for an increased risk of post-infarct left ventricular systolic dysfunction.
Zhu Y; Liu K; Meng S; Jia R; Lei X; Chen M; Zou K; Zhu H; Jin Z
Cardiovasc Diabetol; 2020 Jul; 19(1):101. PubMed ID: 32622355
[TBL] [Abstract][Full Text] [Related]
20. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
